Chimeric antigen receptor T cell therapy reduces vaccine immunity, with many patients lacking seroprotection despite stable antibody levels.
RA patients on upadacitinib and methotrexate showed robust antibody and T-cell responses to the recombinant zoster vaccine over 60 weeks. The vaccine maintained a satisfactory humoral response in 71.4 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results